The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Vincenzo Di Marzo

Endocannabinoid Research Group

Istituto di Chimica Biomolecolare

Consiglio Nazionale delle Ricerche




Name/email consistency: high



  • Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy. 2001 - 2011
  • Italian National Research Council, Pozzuoli, Naples, Italy. 2008
  • Istituto per la Chimica di Molecole di Interesse Biologico, Via Toiano 6, 80072, Arco Felice, Italy. 2000 - 2001
  • School of Biological Sciences, University of Manchester, United Kingdom. 2000


  1. Gut feelings about the endocannabinoid system. Di Marzo, V., Piscitelli, F. Neurogastroenterol. Motil. (2011) [Pubmed]
  2. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Di Marzo, V. Nat. Neurosci. (2011) [Pubmed]
  3. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Di Marzo, V. Pharmacol. Res. (2009) [Pubmed]
  4. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Di Marzo, V., Ligresti, A., Cristino, L. Int. J. Obes. (Lond) (2009) [Pubmed]
  5. CB1 antagonists for obesity--what lessons have we learned from rimonabant? Di Marzo, V., Després, J.P. Nat. Rev. Endocrinol (2009) [Pubmed]
  6. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Di Marzo, V., Côté, M., Matias, I., Lemieux, I., Arsenault, B.J., Cartier, A., Piscitelli, F., Petrosino, S., Alméras, N., Després, J.P. Diabetologia (2009) [Pubmed]
  7. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Di Marzo, V., Verrijken, A., Hakkarainen, A., Petrosino, S., Mertens, I., Lundbom, N., Piscitelli, F., Westerbacka, J., Soro-Paavonen, A., Matias, I., Van Gaal, L., Taskinen, M.R. Eur. J. Endocrinol. (2009) [Pubmed]
  8. CB(1) receptor antagonism: biological basis for metabolic effects. Di Marzo, V. Drug Discov. Today (2008) [Pubmed]
  9. FAAH and anandamide: is 2-AG really the odd one out? Di Marzo, V., Maccarrone, M. Trends Pharmacol. Sci. (2008) [Pubmed]
  10. Endocannabinoids: synthesis and degradation. Di Marzo, V. Rev. Physiol. Biochem. Pharmacol. (2008) [Pubmed]
  11. The endocannabinoid system in obesity and type 2 diabetes. Di Marzo, V. Diabetologia (2008) [Pubmed]
  12. New Potential Therapies from Vanilloid Transient Receptor Cation (TRPV) Channels. Di Marzo, V., Starowicz, K. Curr. Pharm. Des. (2008) [Pubmed]
  13. Targeting the endocannabinoid system: to enhance or reduce?. Di Marzo, V. Nat. Rev. Drug. Discov (2008) [Pubmed]
  14. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?. Di Marzo, V. Nature Clinical Practice. Cardiovascular Medicine (2008) [Pubmed]
  15. Endocannabinoids and the regulation of their levels in health and disease. Di Marzo, V., Petrosino, S. Curr. Opin. Lipidol. (2007) [Pubmed]
  16. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Di Marzo, V., Bisogno, T., De Petrocellis, L. Chem. Biol. (2007) [Pubmed]
  17. Plant, synthetic, and endogenous cannabinoids in medicine. Di Marzo, V., Petrocellis, L.D. Annu. Rev. Med. (2006) [Pubmed]
  18. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Di Marzo, V. Trends Pharmacol. Sci. (2006) [Pubmed]
  19. Endocannabinoid overactivity and intestinal inflammation. Di Marzo, V., Izzo, A.A. Gut (2006) [Pubmed]
  20. Endocannabinoid control of food intake and energy balance. Di Marzo, V., Matias, I. Nat. Neurosci. (2005) [Pubmed]
  21. The biosynthesis, fate and pharmacological properties of endocannabinoids. Di Marzo, V., De Petrocellis, L., Bisogno, T. Handb. Exp. Pharmacol (2005) [Pubmed]
  22. The endocannabinoid system and its therapeutic exploitation. Di Marzo, V., Bifulco, M., De Petrocellis, L. Nat. Rev. Drug. Discov (2004) [Pubmed]
  23. Manipulation of the endocannabinoid system by a general anaesthetic. Di Marzo, V. Br. J. Pharmacol. (2003) [Pubmed]
  24. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. Di Marzo, V., Griffin, G., De Petrocellis, L., Brandi, I., Bisogno, T., Williams, W., Grier, M.C., Kulasegram, S., Mahadevan, A., Razdan, R.K., Martin, B.R. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  25. Anandamide receptors. Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A., Bisogno, T. Prostaglandins Leukot. Essent. Fatty Acids (2002) [Pubmed]
  26. Endovanilloid signaling in pain. Di Marzo, V., Blumberg, P.M., Szallasi, A. Curr. Opin. Neurobiol. (2002) [Pubmed]
  27. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Di Marzo, V., Bisogno, T., De Petrocellis, L., Brandi, I., Jefferson, R.G., Winckler, R.L., Davis, J.B., Dasse, O., Mahadevan, A., Razdan, R.K., Martin, B.R. Biochem. Biophys. Res. Commun. (2001) [Pubmed]
  28. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Di Marzo, V., Lastres-Becker, I., Bisogno, T., De Petrocellis, L., Milone, A., Davis, J.B., Fernandez-Ruiz, J.J. Eur. J. Pharmacol. (2001) [Pubmed]
  29. Anandamide: some like it hot. Di Marzo, V., Bisogno, T., De Petrocellis, L. Trends Pharmacol. Sci. (2001) [Pubmed]
  30. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Di Marzo, V., Melck, D., Orlando, P., Bisogno, T., Zagoory, O., Bifulco, M., Vogel, Z., De Petrocellis, L. Biochem. J. (2001) [Pubmed]
  31. Cannabimimetic fatty acid derivatives in cancer and inflammation. Di Marzo, V., Melck, D., De Petrocellis, L., Bisogno, T. Prostaglandins Other Lipid Mediat. (2000) [Pubmed]
  32. Endocannabinoids and multiple sclerosis: a blessing from the 'inner bliss'?. Di Marzo, V., Bifulco, M., De Petrocellis, L. Trends Pharmacol. Sci. (2000) [Pubmed]
  33. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R., Brotchie, J.M. FASEB J. (2000) [Pubmed]
  34. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. Di Marzo, V., Breivogel, C.S., Tao, Q., Bridgen, D.T., Razdan, R.K., Zimmer, A.M., Zimmer, A., Martin, B.R. J. Neurochem. (2000) [Pubmed]
WikiGenes - Universities